Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H27N5O4.ClH |
Molecular Weight | 473.953 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12CCCC[C@@]1([H])N(CCN2C(=O)C3=CC=CO3)C4=NC(N)=C5C=C(OC)C(OC)=CC5=N4
InChI
InChIKey=SKDIDWRQDBIQBS-MCJVGQIASA-N
InChI=1S/C23H27N5O4.ClH/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18;/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26);1H/t16-,17+;/m0./s1
Molecular Formula | C23H27N5O4 |
Molecular Weight | 437.4916 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23767297Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23767297
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/18037913 | https://www.ncbi.nlm.nih.gov/pubmed/15598431
CYCLAZOSIN HYDROCHLORIDE is a quinazoline derivative pharmacologically characterized as putative a1B-adrenoceptor antagonist.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL223 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
3.24 nM [Ki] | ||
Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
12.3 nM [Ki] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17276073 |
0.135 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18037913
Male C-57 WT mice (22–35 g) were injected s.c. with the putative a1B-adrenoceptor antagonist cyclazosin (1.0mg/kg). Cyclazosin was administered 30 min prior to the injection of vehicle (1 ml/kg) or MDMA (20mg/kg). The putative a1B-adrenoceptor antagonist cyclazosin (1mg/kg) in vehicle experiments did not significantly alter the body temperature when compared to vehicle group. The pretreatment of mice with cyclazosin significantly altered the effect of MDMA on core body temperature
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23767297
Sections of the abdominal aorta, obtained from adult female New Zealand rabbits, were treated with agonists and antagonists of adrenergic receptors. Administration of cyclazosin at a dose of 0.002 μM caused a decrease in the muscle tonus of -0.49 ± 0.10 mN. After blockade of the α1B-adrenergic receptor by 0.02 mkM cyclazosin, the administration of 0.05 μM phenylephrine resulted in an increase of the aortic muscle tonus of 1.49 ± 0.14 mN.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:03:54 GMT 2023
by
admin
on
Sat Dec 16 09:03:54 GMT 2023
|
Record UNII |
RLN802138L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9869475
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
DTXSID1040453
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
146929-33-1
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
RLN802138L
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
PRIMARY | |||
|
184033-31-6
Created by
admin on Sat Dec 16 09:03:54 GMT 2023 , Edited by admin on Sat Dec 16 09:03:54 GMT 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |